A powerful forum for the leaders developing treatments and cures in neuroscience and central nervous system. Accelerating investment, development and commercialisation in neuroscience. 

This is a 40-person Chatham House Rule, formatted forum in which industry leaders discuss and shape the future of their sector behind closed doors. They are hollow-square formats and not your standard one-dimensional meeting format meaning all executives engage in meaningful strategic and sector debate and discussion. The forums will address the key industry challenges head on, providing genuine outcomes for the executives and the sector as a whole.

The 40 seats will be allocated with no fewer than 36 executives and KOLs, with the remaining seats taken by  Forum Co-Hosts that may include 1 Pharma, 1 Global Advisory, 1 Law Firm, 1 CRO and / or 1 Investor. The GEO breakdown will roughly be 40 US, 50% UK and EU and 10% RoW and as we are focused on diversity, we are looking to ensure that at least 30% of the attendees are women Executives.

Company leaders who are growing and developing the businesses which will change the lives of millions of patients with central nervous system issues and neurodegenerative diseases. It is not for scientists, researchers and technical job titles in the neuroscience and CNS space.

CEOs and/or event partners put forward case studies – either success stories or current challenges and use the group as “consultants”. Each case study follows this format:

Headline – short and enticing
Nutshell – a concise statement of the issue
Background – the players, the issue, what was at stake, etc
What Was Tried? - what worked and what didn’t
Questions - clarifying questions from the group.
Peer Consultation
Review - what are you taking back with you? what will you try?

Executives can explore in this session:

The Industry and Business Agenda
Industry collaboration and a patient-centric approach to treatment R&D, the huge implications of neurodegenerative disease drains on country economies, innovative deal structures, licensing and business development models

The R&D Agenda
What is needed to address R&D failures and deliver success stories in the space, the most exciting and promising discovery areas

The Investment Agenda
Overcoming funding, finance and investment challenges in CNS and neuroscience, addressing the drug failures in the eyes of investors, what’s need to attract significant investment into the space

The Future Agenda
The new frontiers for neuroscience and neurotechnology

Are you interested in a seat at the table and would like to be considered for an invitation to attend the Neuroscience & CNS Forum?